{
    "nctId": "NCT00371345",
    "briefTitle": "Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer",
    "officialTitle": "Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/Neu-Positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 92,
    "primaryOutcomeMeasure": "Number of Participants With Objective Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* females, 18 or older\n* recurrent, locally advanced, or metastatic breast cancer with expression of ER/PR receptor and/or overexpression of Her2/neu\n* paraffin-embedded tissue block must be available\n* measurable disease\n* prior chemotherapy with an anthracycline and/or a taxane (neoadjuvant, adjuvant, or metastatic setting)\n* 0, 1 or 2 chemotherapies in the metastatic setting\n* adequate organ function\n\nExclusion Criteria:\n\n* Metastatic disease confined to bone only\n* Symptomatic central nervous system (CNS) metastasis\n* Concurrent medical condition which may increase the risk of toxicity\n* Unable to take oral medication",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}